Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH). However, there is little information about the transition strategy between these two ETRAs. We aimed to evaluate the safety and effic...

Full description

Saved in:
Bibliographic Details
Main Authors: Su-Gang Gong, Lan Wang, Bigyan Pudasaini, Ping Yuan, Rong Jiang, Qin-Hua Zhao, Jing He, Rui Zhang, Wen-hui Wu, Jin-Ming Liu, Cai-cun Zhou
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Canadian Respiratory Journal
Online Access:http://dx.doi.org/10.1155/2018/9836820
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items